PMV Pharmaceuticals
Develops a precision-oncology therapy for cancers with TP53 Y220C mutations.
Something off on this page? Send us feedback.
Profile
Develops small-molecule therapies that seek to reactivate mutant p53 proteins in cancer. Its clinical program is centered on rezatapopt, a tumor-agnostic therapy being studied in advanced solid tumors with TP53 Y220C mutations.
Develops selective small-molecule therapies aimed at reactivating mutant p53 proteins that have lost tumor-suppressor function. Research is focused on precision-oncology treatments for cancers with specific p53 mutations.
Rezatapopt is the central program, a p53-Y220C reactivator in the ongoing PYNNACLE Phase 2 study for advanced solid tumors. The previous rezatapopt-pembrolizumab combination cohort was discontinued, leaving monotherapy as the current development path.
Based in Princeton, New Jersey, operations remain a clinical-development and research business. Progress depends on conducting clinical studies, obtaining regulatory approval, manufacturing and commercializing any approved therapy, and raising additional capital when needed.
Company facts
Key statistics
Analysts
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| May 13, 2026 | Oppenheimer | Reiterate | Outperform | $6 | $5 |
Earnings
EPSReportedEstimate
RevenueReportedEstimate
Financials
Balance sheet, Jun 30, 2026Cash & short-term investments $79.4M · Total debt $217.0K · Total assets $82.1M · Shareholders' equity $71.5M
- Revenue
- $0
- Operating income
- −$18.9M
- Net income
- −$18.1M
Dividends
No dividends on record.
Ownership
| Institutions70 holders · as of Mar 31, 2026 | 69.14% | 36.96M shares | |
| Insiders4 holders · as of Oct 29, 2025 | 1.31% | 699.9K shares | |
| Strategic holders1 holder · as of Feb 4, 2022 | 4.75% | 2.54M shares | |
| Otherremainder | 24.80% | 13.26M shares |
53.46M company shares as of Sep 1, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
BML Capital Management, LLCInstitution | 9.95% | 5.32M | 13Fas of Mar 31, 2026 |
BML Investment Partners, L.P.Institution | 9.90% | 5.29M | 13Gfiled Feb 9, 2026 ↗ |
Tang Capital Management LLCInstitution | 7.94% | 4.25M | 13Fas of Mar 31, 2026 |
Sio Capital Management, LLCInstitution | 5.76% | 3.08M | 13Fas of Mar 31, 2026 |
Arrowmark Colorado Holdings LLCInstitution | 5.37% | 2.87M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Oct 23, 2025 | Orbimed Advisors LLC | 10 percent owner | −1,000,000 | $1.52 |
| Sep 10, 2025 | Orbimed Advisors LLC | 10 percent owner | −500,000 | $1.80 |
Peers
Not reported.